Back
Eli Lilly's Ovarian Cancer Drug Wins FDA Breakthrough Designation
Back
Stock News
Themes
Eli Lilly's Ovarian Cancer Drug Wins FDA Breakthrough Designation
Donald Trump
Eli Lilly's Ovarian Cancer Drug Wins FDA Breakthrough Designation
Edgen Stock
·
Jan 20 2026, 15:09
Share to
Share to
Copy link
LLY
+1.69%
source:
[1] Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
Recommend
Regentis Reports Breakthrough Cartilage Regeneration in 2-Year GelrinC Study
Jan 20 2026, 14:36
ServiceNow Taps OpenAI to Embed AI Agents in Enterprise Software
Jan 20 2026, 14:32
Bristol Myers Taps Microsoft AI for Lung Cancer Detection
Jan 20 2026, 14:26
Edgen Stock·Jan 20 2026, 15:09Edgen Stock·Jan 20 2026, 15:09
Edgen Stock·Jan 20 2026, 15:09